CBAY — CymaBay Therapeutics Share News
0.000.00%
Last trade - 00:00- $3.73bn
- $3.44bn
- $31.07m
Brief: Cymabay Therapeutics Long-Term Open Label Study Finds Treatment With Seladelpar For Two Years Improves Key Liver Biomarkers In Patients With PBC
Cymabay Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Cymabay Reports Posts Quarterly Loss Per Share Of 33 Cents
Cymabay Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview
Cymabay Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-New Fortress Energy, PMV Pharmaceuticals, Rockwell Automation
Brief: Cymabay Reports Second Quarter And Six Months Ended June 30, 2021 Financial Results And Provides Corporate Update
Cymabay Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Cymabay Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Cymabay Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Brief: Cymabay Announces $100 Mln Non-Dilutive Financing With Abingworth
Brief: Cymabay Therapeutics Presents Positive Pbc Data At International Liver Congress™ 2021
Cymabay Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Cymabay Reports Qtrly Loss Per Share $0.25
Cymabay Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Cymabay Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: CymaBay Appoints Thomas Wiggans And Janet Dorling To Board
Brief: Cymabay Therapeutics Reports Presentation Of Positive Results From Study Evaluating Seladelpar
Brief: Cymabay Reports Third Quarter 2020 Financial Results And Provides Corporate Update